Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits

[1]  G. Taglialatela,et al.  Near infrared light decreases synaptic vulnerability to amyloid beta oligomers , 2017, Scientific Reports.

[2]  Gang Li,et al.  PLD1 promotes dendritic spine development by inhibiting ADAM10-mediated N-cadherin cleavage , 2017, Scientific Reports.

[3]  C. Revnic,et al.  THE EFFECT OF SERUM FACTORS FROM PATIENTS WITH/WITHOUT ESSENTIAL HYPERTENSIOIN ON MEMBRANE RECEPTORS FROM RAT CEREBRAL CORTEX VASCULAR AND CARDIAC MUSCLE CELLS , 2017, Alzheimer's & Dementia.

[4]  P. Thomas,et al.  Targeting phospholipase D in cancer, infection and neurodegenerative disorders , 2017, Nature Reviews Drug Discovery.

[5]  G. Logroscino,et al.  Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease , 2016, BioMed research international.

[6]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[7]  G. Taglialatela,et al.  A method to determine insulin responsiveness in synaptosomes isolated from frozen brain tissue , 2016, Journal of Neuroscience Methods.

[8]  A. Kurosky,et al.  Fear potentiated startle increases phospholipase D (PLD) expression/activity and PLD-linked metabotropic glutamate receptor mediated post-tetanic potentiation in rat amygdala , 2016, Neurobiology of Learning and Memory.

[9]  Balaji Krishnan.  Amygdala-Hippocampal Phospholipase D (PLD) Signaling As Novel Mechanism of Cocaine-Environment Maladaptive Conditioned Responses , 2016, The international journal of neuropsychopharmacology.

[10]  A. Palmeri,et al.  Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory , 2016, Scientific Reports.

[11]  M. Frohman,et al.  Physiological and pathophysiological roles for phospholipase D , 2015, Journal of Lipid Research.

[12]  N. Vitale,et al.  PLD1 participates in BDNF-induced signalling in cortical neurons , 2015, Scientific Reports.

[13]  H. Braak,et al.  The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. , 2015, Brain : a journal of neurology.

[14]  K. Stover,et al.  Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer's disease , 2015, Behavioural Brain Research.

[15]  M. Frohman.  The phospholipase D superfamily as therapeutic targets. , 2015, Trends in pharmacological sciences.

[16]  E. Hattingen,et al.  Impaired brain development and reduced cognitive function in phospholipase D-deficient mice , 2014, Neuroscience Letters.

[17]  W. Rosenblum.  Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult , 2014, Neurobiology of Aging.

[18]  D. Swaab,et al.  Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase? , 2013, Journal of Alzheimer's disease : JAD.

[19]  Xin-Fu Zhou,et al.  Amyloid beta1–42 (Aβ42) up‐regulates the expression of sortilin via the p75NTR/RhoA signaling pathway , 2013, Journal of neurochemistry.

[20]  E. Marcello,et al.  ADAM10 in Synaptic Physiology and Pathology , 2013, Neurodegenerative Diseases.

[21]  Dong-Min Yin,et al.  PLD1 Negatively Regulates Dendritic Branching , 2012, The Journal of Neuroscience.

[22]  G. Taglialatela,et al.  α‐Synuclein oligomers oppose long‐term potentiation and impair memory through a calcineurin‐dependent mechanism: relevance to human synucleopathic diseases , 2012, Journal of neurochemistry.

[23]  P. Shinnick‐Gallagher,et al.  Dopamine-Induced Plasticity, Phospholipase D (PLD) Activity and Cocaine-Cue Behavior Depend on PLD-Linked Metabotropic Glutamate Receptors in Amygdala , 2011, PloS one.

[24]  O. Arancio,et al.  Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits , 2010, The Journal of Neuroscience.

[25]  G. Taglialatela,et al.  Amyloid‐β oligomers impair fear conditioned memory in a calcineurin‐dependent fashion in mice , 2010, Journal of neuroscience research.

[26]  M. Wakelam,et al.  Inter-regulatory dynamics of phospholipase D and the actin cytoskeleton. , 2009, Biochimica et biophysica acta.

[27]  G. Taglialatela,et al.  Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition , 2009, Behavioural Brain Research.

[28]  Thomas Arendt,et al.  Synaptic degeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.

[29]  D. Small.  Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression? , 2008, Trends in molecular medicine.

[30]  T. Wieland,et al.  Direct stimulation of receptor‐controlled phospholipase D1 by phospho‐cofilin , 2007, The EMBO journal.

[31]  J. D. McGaugh,et al.  Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice , 2007, Neurobiology of Disease.

[32]  K. Chung,et al.  Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease , 2007, Neurobiology of Aging.

[33]  Yong-Sun Kim,et al.  Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer's disease patients , 2006, Neuroscience Letters.

[34]  P. Greengard,et al.  Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Greengard,et al.  Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Klein.  Functions and pathophysiological roles of phospholipase D in the brain , 2005, Journal of neurochemistry.

[37]  D. Small,et al.  Mechanisms of synaptic homeostasis in Alzheimer's disease. , 2004, Current Alzheimer research.

[38]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[39]  Y. Humeau,et al.  A role for phospholipase D1 in neurotransmitter release , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Ryu,et al.  Dual requirement for rho and protein kinase C in direct activation of phospholipase D1 through G protein-coupled receptor signaling. , 2000, Molecular biology of the cell.

[41]  J. Pettegrew,et al.  Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell. , 1996, Journal of lipid mediators and cell signalling.

[42]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[43]  H. Braak,et al.  Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder , 1994, Neurobiology of Aging.

[44]  W. Clark,et al.  Accurate freehand injection into the lateral brain ventricle of the conscious mouse. , 1968, Journal of applied physiology.

[45]  U. Sengupta,et al.  Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. , 2017, Methods in molecular biology.

[46]  Fei Liu,et al.  Tau and neurodegenerative disease: the story so far , 2016, Nature Reviews Neurology.

[47]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[48]  G. Feng,et al.  Acute brain slice methods for adult and aging animals: application of targeted patch clamp analysis and optogenetics. , 2014, Methods in molecular biology.

[49]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.